HomeCompareOCEL vs SBUX

OCEL vs SBUX: Dividend Comparison 2026

OCEL yields 72.93% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEL wins by $1.05M in total portfolio value
10 years
OCEL
OCEL
● Live price
72.93%
Share price
$2.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.20M
Annual income
$325,655.22
Full OCEL calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — OCEL vs SBUX

📍 OCEL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCELSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEL + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEL pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEL
Annual income on $10K today (after 15% tax)
$6,198.72/yr
After 10yr DRIP, annual income (after tax)
$276,806.94/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, OCEL beats the other by $220,842.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEL + SBUX for your $10,000?

OCEL: 50%SBUX: 50%
100% SBUX50/50100% OCEL
Portfolio after 10yr
$680.8K
Annual income
$195,747.67/yr
Blended yield
28.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

OCEL
No analyst data
Altman Z
-38.0
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEL buys
0
SBUX buys
0
No recent congressional trades found for OCEL or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCELSBUX
Forward yield72.93%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$1.20M$157.5K
Annual income after 10y$325,655.22$65,840.13
Total dividends collected$1.03M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: OCEL vs SBUX ($10,000, DRIP)

YearOCEL PortfolioOCEL Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$17,993$7,292.62$11,107$407.21+$6.9KOCEL
2$31,515$12,262.92$12,512$626.87+$19.0KOCEL
3$53,795$20,073.98$14,366$978.69+$39.4KOCEL
4$89,585$32,023.91$16,929$1,557.50+$72.7KOCEL
5$145,696$49,840.41$20,658$2,543.80+$125.0KOCEL
6$231,650$75,755.11$26,406$4,302.22+$205.2KOCEL
7$360,433$112,567.38$35,877$7,622.00+$324.6KOCEL
8$549,352$163,689.57$52,741$14,352.64+$496.6KOCEL
9$820,973$233,165.47$85,676$29,243.03+$735.3KOCEL
10$1,204,096$325,655.22$157,513$65,840.13+$1.05MOCEL

OCEL vs SBUX: Complete Analysis 2026

OCELStock

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.

Full OCEL Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this OCEL vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEL vs SCHDOCEL vs JEPIOCEL vs OOCEL vs KOOCEL vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.